Effect of radiofrequency ablation combined with sorafenib in treating primary hepatocellular carcinoma
Wu Xiaoyong
Zhang Yanzhong
Zhang Yu
Ma Haining
Huang Bo
Abstract：Objective To explore the effect of radiofrequency ablation combined with sorafenib in treating primary hepatocellular carcinoma.Methods Totally 90 patients with primary hepatocellular carcinoma from January 2011 to July 2012 were sequentially divided into control group (45 cases) receiving radiofrequency ablation and observation group (45 cases) receiving radiofrequency ablation combined with sorafenib (400 mg/time,2 times/d).The time interval between two times of ablation,totally effective rate,survival rates 3,6 months and 3 years after treatment were compared between groups.Results The time interval between two times of ablation in observation group was significantly longer than that in control group [(5.2 ± 1.2) months vs (3.9 ± 1.3) months] (P ＜0.01);the total effective rate in observation group was significantly higher than that in control group [60.0％ (27/45) vs 33.3％ (15/45)] (P ＜ 0.05);the survival rates 6,12 months and 3 years after treatment in observation group were significantly higher than those in control group [75.6％ (34/45) vs 38.9％ (22/45),37.8％ (17/45)vs 11.1％ (5/45),22.2％ (10/45)vs 6.7％ (3/45)] (P＜0.05).Conclusion Radiofrequency ablation combined with sorafenib is effective in treating primary hepatocellular carcinoma.
Keywords：Primary hepatocellular carcinomaRadiofrequency ablationSorafenibEfficacy
Publication Date：2016-05-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 688-690 )